GoodRx (NASDAQ:GDRX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, Zacks.com reports. The brokerage currently has a $49.00 price target on the stock. Zacks Investment Research‘s price objective points to a potential upside of 13.09% from the company’s current price.

According to Zacks, “GoodRx Holdings Inc. provides consumer-focused digital healthcare platform. GoodRx Holdings Inc. is based in Santa Monica, California. “

GDRX has been the topic of a number of other reports. Royal Bank of Canada raised GoodRx from a “sector perform” rating to an “outperform” rating and set a $56.00 price objective on the stock in a report on Thursday, November 19th. UBS Group started coverage on GoodRx in a report on Monday, October 19th. They issued a “buy” rating and a $64.00 price objective on the stock. JPMorgan Chase & Co. reissued an “underweight” rating and set a $29.00 target price on shares of GoodRx in a report on Wednesday, November 18th. The Goldman Sachs Group reduced their target price on GoodRx from $49.00 to $44.00 and set a “neutral” rating on the stock in a report on Monday, November 23rd. Finally, Cowen started coverage on GoodRx in a report on Monday, October 19th. They set an “outperform” rating and a $63.00 target price on the stock. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $50.43.

NASDAQ GDRX traded down $0.46 on Wednesday, reaching $43.33. The stock had a trading volume of 1,489,585 shares, compared to its average volume of 1,841,852. The company has a debt-to-equity ratio of 0.91, a current ratio of 19.63 and a quick ratio of 19.63. The stock’s fifty day moving average is $41.67. GoodRx has a 1-year low of $33.51 and a 1-year high of $64.22.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings data on Thursday, November 12th. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.12. The firm had revenue of $140.40 million during the quarter, compared to analyst estimates of $135.05 million. The firm’s revenue for the quarter was up 37.9% on a year-over-year basis. On average, equities analysts anticipate that GoodRx will post -0.51 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the stock. Stuart Chaussee & Associates Inc. acquired a new stake in GoodRx in the third quarter valued at about $49,000. Bainco International Investors acquired a new stake in GoodRx in the fourth quarter valued at about $41,000. Crewe Advisors LLC acquired a new stake in GoodRx in the third quarter valued at about $83,000. Evolution Wealth Advisors LLC acquired a new stake in GoodRx in the third quarter valued at about $111,000. Finally, Emerald Advisers LLC acquired a new stake in GoodRx in the third quarter valued at about $125,000. 13.24% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc is a holding company. The company, through its subsidiaries, owns and operates a prescription drug price comparison platform using data from local and mail-order pharmacies in the United States. It also provides pharmacy coupons to customers. The company offers generic and brand name pricing; alerts clients on manufacturer co-pay cards, pharmacy discounts, and state discount programs; and provides tips on slashing drug prices.

Recommended Story: Why is total return important?

Get a free copy of the Zacks research report on GoodRx (GDRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.